Anti-BAFF-anti-IL-17 bispecific monoclonal antibody - Eli Lilly
Latest Information Update: 10 Mar 2016
At a glance
- Originator Eli Lilly
- Class Antibodies
- Mechanism of Action B cell activating factor inhibitors; Interleukin-17 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 25 Jan 2016 Phase-I clinical trials in Immunological disorders in USA (unspecified route) before January 2016